Skip To Main Content
Richard E Chaisson on Muck Rack

Richard E Chaisson

As seen in: Nature, PLOS Medicine, The Conversation, The New England Journal of Medicine, City Press, Medscape, The Lancet, AllAfrica, Modern Ghana, Healio and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Richard E

Contact Richard E, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Author Correction: Risk-stratified treatment for drug-susceptible pulmonary tuberculosis - Nature Communications

|
By Richard E Chaisson, John Johnson, Radojka M. Savic
| Nature Verified
Correction to: Nature Communications https://doi.org/10.1038/s41467-024-53273-7, published online 30 October 2024 In the version of the article initially published, Amina Jindani and Thomas Harrison (both St. George’s, University of London, London, UK) were missing from the author list and have now been added.
Open in Who Shared View Duplicates (3) Issue with article?

Risk-stratified treatment for drug-susceptible pulmonary tuberculosis - Nature Communications

|
By Richard E Chaisson, John Johnson, Radojka M. Savic
| Nature Verified
Abstract The Phase 3 randomized controlled trial, TBTC Study 31/ACTG A5349 (NCT02410772) demonstrated that a 4-month rifapentine-moxifloxacin regimen for drug-susceptible pulmonary tuberculosis was safe and effective. The primary efficacy outcome was 12-month tuberculosis disease free survival, while the primary safety outcome was the proportion of grade 3 or higher adverse events during the treatment period.
Open in Who Shared Issue with article?

Restocking the tuberculosis drug arsenal - Nature Medicine

|
By Eric Nuermberger, Richard E Chaisson
| Nature Verified
After many lean years, important progress has been made in updating the anti-tuberculosis drug armamentarium; a new drug that targets bacterial protein synthesis is one of several that could help transform the treatment of this neglected and deadly disease.
Open in Who Shared Issue with article?
See all 15 articles